Literature DB >> 2139556

Serotonin-specific drugs for anxiety and depressive disorders.

D S Charney1, J H Krystal, P L Delgado, G R Heninger.   

Abstract

In the last few years there has been a marked increase in knowledge regarding the possible roles of serotonin neuronal dysfunction in the pathophysiology and treatment of anxiety and depressive disorders. During the same time period, new drugs with specific actions on serotonin function have become available for clinical testing. This review provides an update on the efficacy of serotonin-specific drugs for anxiety and depressive disorders.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2139556     DOI： 10.1146/annurev.me.41.020190.002253

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  11 in total

Review 1.  The impact of sex as a biological variable in the search for novel antidepressants.

Authors:  Alexia V Williams; Brian C Trainor
Journal:  Front Neuroendocrinol       Date:  2018-05-31       Impact factor: 8.606

2.  Dopamine receptor stimulation does not modulate the loudness dependence of the auditory evoked potential in humans.

Authors:  Barry V O'Neill; Rodney J Croft; Sumie Leung; Valérie Guille; Matthew Galloway; K Luan Phan; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

3.  Opiate exposure and withdrawal dynamically regulate mRNA expression in the serotonergic dorsal raphe nucleus.

Authors:  J W Lunden; L G Kirby
Journal:  Neuroscience       Date:  2013-09-20       Impact factor: 3.590

4.  Morphine history sensitizes postsynaptic GABA receptors on dorsal raphe serotonin neurons in a stress-induced relapse model in rats.

Authors:  D R Staub; J W Lunden; A M Cathel; E L Dolben; L G Kirby
Journal:  Psychoneuroendocrinology       Date:  2011-11-01       Impact factor: 4.905

5.  Increased serotonin-1A (5-HT1A) autoreceptor expression and reduced raphe serotonin levels in deformed epidermal autoregulatory factor-1 (Deaf-1) gene knock-out mice.

Authors:  Margaret Czesak; Brice Le François; Anne M Millar; Mariam Deria; Mireille Daigle; Jane E Visvader; Hymie Anisman; Paul R Albert
Journal:  J Biol Chem       Date:  2012-01-09       Impact factor: 5.157

6.  Long-term modulation of presynaptic 5-HT-output: experimentally induced changes in cortical 5-HT-transporter density, tryptophan hydroxylase content and 5-HT innervation density.

Authors:  G Huether; D Zhou; E Rüther
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

7.  Corticotropin-releasing factor increases GABA synaptic activity and induces inward current in 5-hydroxytryptamine dorsal raphe neurons.

Authors:  Lynn G Kirby; Emily Freeman-Daniels; Julia C Lemos; John D Nunan; Christophe Lamy; Adaure Akanwa; Sheryl G Beck
Journal:  J Neurosci       Date:  2008-11-26       Impact factor: 6.167

8.  Effect of acute and repeated administration of 5-HT1A receptor agonists on 5-HT release in rat brain in vivo.

Authors:  T Sharp; R McQuade; S Bramwell; S Hjorth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

Review 9.  Transcriptional dys-regulation in anxiety and major depression: 5-HT1A gene promoter architecture as a therapeutic opportunity.

Authors:  Paul R Albert; Laura M Fiori
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 10.  Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness.

Authors:  Paul R Albert; Brice Le François; Anne M Millar
Journal:  Mol Brain       Date:  2011-05-27       Impact factor: 4.041
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.